Esperion to Participate in Piper Sandler 37th Annual Healthcare Conference
Esperion (NASDAQ: ESPR) will present at the Piper Sandler 37th Annual Healthcare Conference in New York on December 3, 2025 at 3:30 p.m. ET.
Investors can access a live webcast on Esperion's investor website; a replay will be available approximately two hours after the call and archived for about 90 days. Esperion is a commercial-stage biopharmaceutical company developing oral, once-daily, non-statin medicines for patients with elevated LDL-C, supported by the nearly 14,000-patient CLEAR Cardiovascular Outcomes Trial. The company is advancing next-generation ATP citrate lyase inhibitors (ACLYi) and pursuing commercial execution and international partnerships.
Esperion (NASDAQ: ESPR) parteciperà alla Piper Sandler 37th Annual Healthcare Conference a New York il 3 dicembre 2025 alle 15:30 ora ET.
Gli investitori possono accedere a una diretta webcast sul sito degli investitori di Esperion; una replica sarà disponibile circa due ore dopo la conferenza e archiviata per circa 90 giorni. Esperion è una biotech farmaceutica a stadio commerciale che sviluppa farmaci orali, una dose giornaliera, non statine, per pazienti con LDL-C elevato, supportata dall quasi 14.000 partecipanti allo studio CLEAR Cardiovascular Outcomes Trial. L'azienda sta avanzando con inibitori di ACLY di prossima generazione (ACLYi) e perseguendo l'esecuzione commerciale e partnership internazionali.
Esperion (NASDAQ: ESPR) participará en la Piper Sandler 37th Annual Healthcare Conference en Nueva York el 3 de diciembre de 2025 a las 3:30 p.m. hora del Este.
Los inversores pueden acceder a una transmisión en vivo en el sitio web para inversores de Esperion; una repetición estará disponible aproximadamente dos horas después de la llamada y quedará archivada por unos 90 días. Esperion es una empresa biofarmacéutica en fase comercial que desarrolla medicamentos orales, de dosis única diaria, no estatinas, para pacientes con LDL-C elevado, respaldada por el casi 14.000 pacientes en el ensayo CLEAR Cardiovascular Outcomes Trial. La empresa está avanzando con inhibidores de ACLY de próxima generación (ACLYi) y persiguiendo la ejecución comercial y asociaciones internacionales.
Esperion (NASDAQ: ESPR)는 뉴욕에서 열리는 파이퍼 샌들러 37회 연례 헬스케어 컨퍼런스에 2025년 12월 3일 동부표준시 오후 3:30에 발표합니다.
투자자는 Esperion의 투자자 웹사이트에서 라이브 웨비캐스트에 접속할 수 있으며, 콜 이후 약 두 시간 후에 재방송이 가능하고 약 90일 동안 보관됩니다. Esperion은 LDL-C가 상승한 환자를 위한 경구 한 번 복용의 비스타틴 제제를 개발하는 상업 단계의 생물의약 회사이며, 거의 14,000명 참여자의 CLEAR Cardiovascular Outcomes Trial로 뒷받침됩니다. 또한 차세대 ATP citrate lyase 억제제(ACLYi)를 개발 중이며 상업적 실행과 국제 파트너십을 추진하고 있습니다.
Esperion (NASDAQ: ESPR) participera à la Piper Sandler 37e conférence annuelle sur les soins de santé à New York le 3 décembre 2025 à 15h30, heure de l’Est.
Les investisseurs peuvent accéder à une webdiffusion en direct sur le site des investisseurs d’Esperion ; une rediffusion sera disponible environ deux heures après l’appel et sera archivée pour environ 90 jours. Esperion est une société biopharmaceutique en phase commerciale qui développe des médicaments oraux, quotidiens et non statines, pour les patients présentant un LDL-C élevé, soutenue par le presque 14 000 participants à l’essai CLEAR Cardiovascular Outcomes Trial. L’entreprise fait progresser des inhibiteurs de l’ACLY de prochaine génération (ACLYi) et poursuit l’exécution commerciale et des partenariats internationaux.
Esperion (NASDAQ: ESPR) wird auf der Piper Sandler 37th Annual Healthcare Conference in New York am 3. Dezember 2025 um 15:30 Uhr ET auftreten.
Investoren können auf einem Live-Webcast auf Esperions Investorenwebsite zugreifen; eine Aufzeichnung wird etwa zwei Stunden nach dem Call verfügbar sein und für ca. 90 Tage archiviert. Esperion ist ein kommerziell tätiges Biopharmaunternehmen, das orale, täglich einzunehmende, nicht‑statinbasierte Medikamente für Patienten mit erhöhtem LDL-C entwickelt und durch die fast 14.000‑Patienten des CLEAR Cardiovascular Outcomes Trial gestützt wird. Das Unternehmen treibt Next‑Generation-ATP‑citratlyase-Inhibitoren (ACLYi) voran und verfolgt kommerzielle Umsetzung und internationale Partnerschaften.
Esperion (NASDAQ: ESPR) ستقدم عرضاً في المؤتمر الصحي السنوي السابع والثلاثين لشركة Piper Sandler في نيويورك يوم 3 ديسمبر 2025 الساعة 3:30 مساءً بتوقيت شرق الولايات المتحدة.
يمكن للمستثمرين الوصول إلى بث مباشر على موقع Esperion للمستثمرين؛ ستكون إعادة العرض متاحة نحو ساعتين بعد المكالمة ومؤرشَفة لحوالي 90 يوماً. Esperion هي شركة أدوية حيوية/حيوية صيدلانية في مرحلة تجارية تطور أدوية فموية، مرة يومياً، غير ستاتينية، للمرضى الذين يعانون من ارتفاع LDL-C، مدعومة بتجربة CLEAR Cardiovascular Outcomes Trial التي تضم قرابة 14,000 مشارك. كما تعمل الشركة على مثبطات ACLY من الجيل التالي (ACLYi) وتسعى لتحقيق تنفيذ تجاري وشراكات دولية.
- None.
- None.
ANN ARBOR, Mich., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will present at the Piper Sandler 37th Annual Healthcare Conference in New York on December 3, 2025, at 3:30 p.m. ET.
The live webcast can be accessed on the investor and media section of the Esperion website. Access to the webcast replay will be available approximately two hours after the completion of the call and will be archived on the Company’s website for approximately 90 days.
Esperion Therapeutics
Esperion Therapeutics, Inc. is a commercial stage biopharmaceutical company focused on bringing new medicines to market that address unmet needs of patients and healthcare professionals. The Company developed and is commercializing the only U.S. Food and Drug Administration (FDA) approved oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease and are struggling with elevated low density lipoprotein cholesterol (LDL-C). These medications are supported by the nearly 14,000 patient CLEAR Cardiovascular Outcomes Trial. Esperion continues to build on its success with its next generation program which is focused on developing ATP citrate lyase inhibitors (ACLYi). New insights into the structure and function of ACLYi fully enables rational drug design and the opportunity to develop highly potent and specific inhibitors with allosteric mechanisms.
Esperion continues to evolve into a leading global biopharmaceutical company through commercial execution, international partnerships and collaborations and advancement of its pre-clinical pipeline. For more information, visit esperion.com and follow Esperion on LinkedIn and X.
Esperion Contact Information:
Investors:
Alina Venezia
investorrelations@esperion.com
(734) 887-3903
Media:
Tiffany Aldrich
corporateteam@esperion.com
(616) 443-8438
FAQ
When will Esperion (ESPR) present at the Piper Sandler 37th Annual Healthcare Conference?
How can investors watch the Esperion (ESPR) presentation on December 3, 2025?
How long will the Esperion (ESPR) webcast replay be available?
What product area does Esperion (ESPR) focus on for investors?
What clinical evidence supports Esperion's (ESPR) marketed medicines?
